Sagimet Biosciences Inc. (SGMT)
| Market Cap | 703.41M +159.7% |
| Revenue (ttm) | n/a |
| Net Income | -47.08M |
| EPS | -1.25 |
| Shares Out | 70.91M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 989,107 |
| Open | 10.41 |
| Previous Close | 10.43 |
| Day's Range | 9.82 - 10.54 |
| 52-Week Range | 4.50 - 11.45 |
| Beta | 3.49 |
| Analysts | Buy |
| Price Target | 27.91 (+181.35%) |
| Est. Earnings | Nov 12, 2026 |
About SGMT
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; a... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for SGMT stock is "Buy." The 12-month stock price target is $27.91, which is an increase of 181.35% from the latest price.
News
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing inhibitors of fatty acid synthase (FASN), a key li...
Sagimet announces dosing of first patient in AURORA study
Sagimet Biosciences (SGMT) announced earlier that the first patient has been dosed in AURORA, its U.S. Phase 3 clinical trial of denifanstat in adults and adolescents aged 12 years and…
H.C. Wainwright views Sagimet dosing news as ‘incrementally positive’
H.C. Wainwright analyst Brandon Folkes reiterates a Buy rating on Sagimet Biosciences (SGMT) with a $29 price target following the announcement that the first patient has been dosed in the…
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
With first patient dosed in AURORA Phase 3 clinical trial, Sagimet advances denifanstat's U.S. registrational program, building on positive Phase 3 clinical results in China from license partner Ascle...
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that the posi...
Sagimet Biosciences price target raised to $26 from $25 at Guggenheim
Guggenheim raised the firm’s price target on Sagimet Biosciences (SGMT) to $26 from $25 and keeps a Buy rating on the shares. With the denifanstat acne Phase 3 study planned…
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabol...
Sagimet Biosciences price target raised to $38 from $33 at Oppenheimer
Oppenheimer raised the firm’s price target on Sagimet Biosciences (SGMT) to $38 from $33 and keeps an Outperform rating on the shares. The firm notes Sagimet/Ascletis presented full 52-week Phase…
Sagimet Biosciences price target lowered to $27 from $29 at Citizens
Citizens analyst Jonathan Wolleben lowered the firm’s price target on Sagimet Biosciences (SGMT) to $27 from $29 and keeps an Outperform rating on the shares. Sagimet’s denifanstat is materially deris...
Sagimet Biosciences’ China data strengthens denifanstat case, says Clear Street
Clear Street keeps a buy rating and $28 price target on Sagimet Biosciences (SGMT) after the company presented its Phase 3 ASC40-304 OLE clinical trial data of denifanstat in patients…
Sagimet Biosciences Transcript: KOL event
Denifanstat showed rapid and sustained efficacy in moderate to severe acne, with significant improvements in lesion counts and IGA success rates over 52 weeks and a favorable safety profile. The upcoming U.S. phase III trial will include adolescents and leverage robust compliance strategies.
Sagimet Biosciences Press release: KOL event
Sagimet Biosciences issued a press release on September 30, 2026, disclosing material business information to investors.
Sagimet Biosciences Slides: KOL event
Sagimet Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on September 30, 2026.
Sagimet Biosciences prices 8.75M shares at $10.00 in underwritten offering
Sagimet Biosciences (SGMT) announced the pricing of an underwritten offering of 8,750,010 shares of its Series A common stock at a price of $10.00 per share, or for certain investors…
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
FOSTER CITY, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabo...
Sagimet Biosciences reports results from Phase 3 ASC40-304 OLE clinical trial
Sagimet Biosciences (SGMT) announced positive 52-week results from the Phase 3 ASC40-304 OLE clinical trial of denifanstat in patients with moderate to severe acne vulgaris, conducted by license partn...
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patients Denifanstat showed progressive...
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
FOSTER CITY, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabo...
Sagimet Biosciences resumed with a Sell at Goldman Sachs
Goldman Sachs analyst Andrea Newkirk resumed coverage of Sagimet Biosciences (SGMT) with a Sell rating and $7 price target representing 35% downside. The firm sees “asymmetric downside” into Sagimet’s...
Sagimet Biosciences Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Denifanstat, a novel FASN inhibitor, is advancing rapidly with strong phase III data in acne and MASH, a favorable safety profile, and FDA support for a single pivotal US trial including adolescents. Commercial plans target premium pricing, broad payer coverage, and a flexible launch strategy.
Cantor starts Sagimet at Overweight on potential in acne
Cantor Fitzgerald analyst Yanni Souroutzidis initiated coverage of Sagimet Biosciences (SGMT) with an Overweight rating and no price target The company is developing denifanstat for moderate-to-severe...
Sagimet Biosciences initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald initiated coverage of Sagimet Biosciences (SGMT) with an Overweight rating.
Sagimet Biosciences upgraded to Overweight from Equal Weight at Barclays
Barclays upgraded Sagimet Biosciences (SGMT) to Overweight from Equal Weight with a price target of $18, up from $8. The company’s dermatology prioritization is “smart” and will minimize spend while…
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
FOSTER CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabo...
Sagimet Biosciences advances AURORA clinical trial
Sagimet Biosciences (SGMT) announced that its AURORA Phase 3 clinical trial of FASN inhibitor denifanstat in moderate to severe acne is on track to initiate enrollment in Q4. Published first…